Insight Molecular Diagnostics Inc. Shares Issued, Value, Share-based Payment Arrangement, before Forfeiture
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Insight Molecular Diagnostics Inc. shares issued, value, share-based payment arrangement, before forfeiture for the quarter ending 2026-06-30 was $661.00K, a 31.15% increase year-over-year.
- Insight Molecular Diagnostics Inc. shares issued, value, share-based payment arrangement, before forfeiture for the quarter ending 2026-03-31 was $615.00K, a 30.02% increase year-over-year.
- Insight Molecular Diagnostics Inc. shares issued, value, share-based payment arrangement, before forfeiture for the quarter ending 2025-12-31 was $721.00K, a 44.49% increase year-over-year.
- Insight Molecular Diagnostics Inc. shares issued, value, share-based payment arrangement, before forfeiture for the quarter ending 2025-09-30 was $521.00K, a 15.78% increase year-over-year.
- Insight Molecular Diagnostics Inc. shares issued, value, share-based payment arrangement, before forfeiture for fiscal 2025 was $2.22M, a 26.58% increase from fiscal 2024.
- Insight Molecular Diagnostics Inc. shares issued, value, share-based payment arrangement, before forfeiture for fiscal 2024 was $1.75M, a 36.49% decline from fiscal 2023.
- Insight Molecular Diagnostics Inc. shares issued, value, share-based payment arrangement, before forfeiture for fiscal 2023 was $2.76M, a 72.52% decline from fiscal 2022.
- Insight Molecular Diagnostics Inc. shares issued, value, share-based payment arrangement, before forfeiture for fiscal 2022 was $10.04M, a 46.79% increase from fiscal 2021.
| Period end | Shares Issued, Value, Share-based Payment Arrangement, before Forfeiture 3 month | Shares Issued, Value, Share-based Payment Arrangement, before Forfeiture 12 month |
|---|---|---|
| 2026-06-30 | $661.00K 10-Q · filed 2026-08-10 | $2.52M derived: sum of 4 quarters · filed 2026-08-10 |
| 2026-03-31 | $615.00K 10-Q · filed 2026-05-13 | $2.36M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-12-31 | $721.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $2.22M 10-K · filed 2026-03-26 |
| 2025-09-30 | $521.00K 10-Q · filed 2025-11-10 | $2.00M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-06-30 | $504.00K 10-Q · filed 2026-08-10 | $1.93M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-03-31 | $473.00K 10-Q · filed 2026-05-13 | $1.81M derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | $499.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $1.75M 10-K · filed 2026-03-26 |
| 2024-09-30 | $450.00K 10-Q · filed 2025-11-10 | $1.74M derived: sum of 4 quarters · filed 2025-11-10 |
| 2024-06-30 | $386.00K 10-Q · filed 2025-08-11 | $1.90M derived: sum of 4 quarters · filed 2025-08-11 |
| 2024-03-31 | $418.00K 10-Q · filed 2025-05-12 | $2.34M derived: sum of 4 quarters · filed 2025-05-12 |
| 2023-12-31 | $484.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-24 | $2.76M 10-K · filed 2025-03-24 |
| 2023-09-30 | $608.00K 10-Q · filed 2024-11-12 | $4.89M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | $834.00K 10-Q · filed 2024-08-08 | $7.47M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $834.00K 10-Q · filed 2024-05-15 | $8.87M derived: sum of 4 quarters · filed 2024-05-15 |
| 2022-12-31 | $2.62M derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-16 | $10.04M 10-K · filed 2024-04-16 |
| 2022-09-30 | $3.18M 10-Q · filed 2023-11-09 | $9.13M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $2.23M 10-Q · filed 2023-08-10 | $7.80M derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | $2.01M 10-Q · filed 2023-05-15 | $7.56M derived: sum of 4 quarters · filed 2023-05-15 |
| 2021-12-31 | $1.71M derived: 10-K 12 month − 10-Q 9 month · filed 2023-04-12 | $6.84M 10-K · filed 2023-04-12 |
| 2021-09-30 | $1.85M 10-Q · filed 2022-11-10 | $6.12M derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | $2.00M 10-Q · filed 2022-08-12 | $6.06M derived: sum of 4 quarters · filed 2022-08-12 |
| 2021-03-31 | $1.29M 10-Q · filed 2022-05-12 | $5.42M derived: sum of 4 quarters · filed 2022-05-12 |
| 2020-12-31 | $985.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-11 | $5.07M 10-K · filed 2022-03-11 |
| 2020-09-30 | $1.78M 10-Q · filed 2021-11-09 | $4.87M derived: sum of 4 quarters · filed 2021-11-09 |
| 2020-06-30 | $1.36M 10-Q · filed 2021-08-11 | $3.90M derived: sum of 4 quarters · filed 2021-08-11 |
| 2020-03-31 | $937.00K 10-Q · filed 2021-05-17 | $3.25M derived: sum of 4 quarters · filed 2021-05-17 |
| 2019-12-31 | $786.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-19 | $3.00M 10-K · filed 2021-03-19 |
| 2019-09-30 | $821.00K 10-Q · filed 2020-11-12 | $2.61M derived: sum of 4 quarters · filed 2020-11-12 |
| 2019-06-30 | $701.00K 10-Q · filed 2020-07-29 | $2.13M derived: sum of 4 quarters · filed 2020-07-29 |
| 2019-03-31 | $686.00K 10-Q · filed 2020-05-12 | $1.82M derived: sum of 4 quarters · filed 2020-05-12 |
| 2018-12-31 | $400.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-26 | $1.48M 10-K · filed 2020-03-26 |
| 2018-09-30 | $344.00K 10-Q · filed 2019-11-14 | |
| 2018-06-30 | $389.00K 10-Q · filed 2019-08-14 | |
| 2018-03-31 | $347.00K 10-Q · filed 2019-05-14 | |
| 2017-12-31 | $1.63M 10-K · filed 2019-04-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |
| Cardio Diagnostics Holdings, Inc. (CDIO) | United States | $0.006B | |
| VOLITIONRX LTD (VNRX) | $0.003B | -0.64 | |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |